Navigation Links
Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
Date:1/27/2011

CARY, N.C., Jan. 27, 2011 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study. This achievement solidifies Cetero's position as the unmatched leader in early-phase clinical development and highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.

"We are very proud of this extraordinary accomplishment, which has been made possible by our dedicated staff and loyal clients," said Troy W. McCall, PhD, Chief Executive Officer of Cetero. "One of the best measures of a CRO's capabilities is its depth and breadth of experience. Cetero can offer clients more efficient clinical studies and assurance of high-quality data on time as a result of having more early-phase experience than any other CRO."  

In conducting 20,000 studies over the past 30 years, Cetero has developed considerable experience with normal healthy participants, special populations and patients. Through targeted recruitment strategies and a constantly updated database, Cetero currently delivers a 99 percent on-time recruitment rate.

"Twenty-thousand studies is a significant achievement and truly reflects Cetero's strengths in conducting both traditional clinical trials with normal healthy participants and specialty Phase I and IIa trials with patients," said Alan Copa, PharmD, President, Clinical Operations - Fargo of Cetero. "Cetero's expertise across a wide range of therapeutic areas provides us with insights on drug development strategies in addition to efficient study execution."

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With nearly 30 years of experience from its founding companies, Cetero has conducted more than 20,000 clinical phar
'/>"/>

SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cetero Research Names Dr. Roger Hayes President of Bioanalytical Operations
2. Cetero Research Launches Seminar Series on Accelerated Proof-of-Concept in Drug Development
3. Cetero Research Leads Industry in Human Allergy Models
4. Profil Institutes CEO Presenting on Early Phase Clinical Research in India
5. AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedys Disease)
6. IRBNet Announces Release of National Research Network™ 2010 Benchmark Report
7. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
8. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
9. Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
10. Best Practices, LLC Research Highlights Critical Role of Medical Affairs in New Product Launch Success
11. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... EMERYVILLE, Calif. , June 19, 2013 /PRNewswire/ ... performance management solutions, introduced the next-generation of its ... solution, which allows health plans to provide their ... their populations, health factors, medical and prescription drug ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ...
(Date:6/19/2013)... June 19, 2013  It may seem like an odd ... breast cancer. But these were two of the most talked ... Annual Meeting & Expo that just convened in ... this focus by some of the top internal medicine experts ... with new research that can not only save lives, but ...
(Date:6/18/2013)... NEW YORK , June 18, 2013  Intercept ... stage biopharmaceutical company focused on the development and commercialization ... diseases, today announced the pricing of an underwritten public ... a public offering price of $33.01 per share.  In ... to purchase up to an additional 259,500 shares of ...
Breaking Medicine Technology:MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 2"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 3"Miracle" Breast Cancer Drug and "Youth Hormone" Pill Steal Show at Prestigious Endocrine Society Conference 4Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... (Nasdaq: DVAX ) today reported that it had ... subjects as,part of an environmental exposure chamber study that ... are being screened based on a history of,ragweed allergy ... in,the chamber is being used to select those individuals ...
... Demonstrate Continued Safety, Consistently Positive Clinical ... ... presented today from,Abbott,s SPIRIT III U.S. pivotal clinical trial demonstrated ... Coronary Stent System at one year, including continued,clinical superiority in ...
Cached Medicine Technology:Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 2Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 2Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 3Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 4Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial 5
(Date:6/19/2013)... June 19, 2013 The deadline ... is this Friday, June 21 at midnight ET. ... programs and innovative people who’ve raised the bar ... visit http://www.minonline.com/ima . , Any consumer and ... title is eligible to enter. Additionally, advertising agencies ...
(Date:6/19/2013)... Utah (PRWEB) June 19, 2013 Today, ... Wisconsin Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution ... to Zane Benefits’ website, as part of the Affordable ... small businesses will become available through new state health ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... results of three important studies have been published in ... of the Congress of Neurological Surgeons . ... Wilkins , a part of Wolters Kluwer Health ... using artificial neural networks (ANNs) may improve the ability ... Another study in the June Neurosurgery supports ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Entry Deadline for min’s Integrated Marketing Awards Is This Friday, June 21 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... 2009 Laboratory market projections.NEWARK, N.J., April 14 ... G-2 Reports indicates that the clinical diagnostic lab ... by 2017. An increase in genetic testing, ... expanded access to healthcare are among the key ...
... Maine, April 14 IDEXX Laboratories, Inc. (Nasdaq: ... 2009 first quarter financial results for Friday, April 24, at ... conference call beginning at 9:00 a.m. (eastern) on that day. ... through a link on the IDEXX Web site, ...
... & Spa,Group, Inc. (OTC Bulletin Board: SOKF), a leading operator ... CEO Liu, Tong, CFO Yu, Xia,and corporate secretary Mu, Yan ... earnings results at 9 am EDT on Thursday,April 16, 2009. ... * US/Canada Toll Free Dial-in #: (866) 811 - 8933, ...
... related blindness by almost 35%, study suggests, , , TUESDAY, ... age-related macular degeneration is on the increase, newer treatments ... disease by about 35 percent, new estimates suggest. , ... Disease Control and Prevention, researchers report that as many ...
... Six New Board of Directors Members Also Appointed and ... Bruce R. Korf, MD, PhD, FACMG, of Birmingham, AL ... Medical Genetics (ACMG), the national professional organization for medical ... President Joe Leigh Simpson, MD, FACMG, of Miami, FL ...
... April 14 Continuing a nine-year tradition of putting ... Lines (NYSE: DAL ) employees today presented ... gift of more than 1,250 handmade quilts. Each quilt, ... airline employees and other volunteers on their own time.(Logo: ...
Cached Medicine News:Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 2Health News:Clinical Diagnostic Lab Testing Market to Grow Over 90% through 2017 3Health News:SOKO Fitness & Spa Group, Inc. to hold 2009 Q3 Earnings Call on Apr. 16 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 2Health News:Nearly 18 Million Will Have Macular Degeneration by 2050 3Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 2Health News:Bruce R. Korf, MD, PhD is Named President of the American College of Medical Genetics 3Health News:Delta Employees Blanket Salt Lake City Medical Center With Warm Gifts 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... Synchron LXi 725 clinical system combines ... accurate immunoassay testing capabilities, innovative data ... a single platform. After tests are ... for optimal quality assurance. If reflex ...
... Access immunoassay system is ... benchtop analyzer that performs ... with panels that include ... infectious disease, blood virus, ...
...
Medicine Products: